Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment

Betsy Goodfellow | November 23, 2023 | News story | Medical Communications |  Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis 

Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b trial for patients with ulcerative colitis (UC), having published this data in the Journal of Crohn’s and Colitis.

The trial included 38 patients, with the patients randomised to either receive various doses of the NX-13 or a placebo. NX-13 was well-tolerated in all patients, with no deaths or severe adverse events reported, and only mild to moderate adverse events being observed.

Most patients who received the drug for four weeks showed consistent and rapid clinical improvement in total Mayo score and in symptomatic relief. Endoscopic improvement was observed to correlate closely with symptom improvement.

Advertisement

The drug is now being assessed in the NEXUS trial – a randomised, multi-centre, double-blind, placebo-controlled, multiple dose, statistically powered, phase 2 proof-of-concept study. Results are expected in the fourth quarter of 2024.

Bram Verstockt MD PhD, lead author on the publication, commented: “Despite advances in UC treatments, the need for new and novel therapies such as NX-13 remains highly important for patients. The early signs of efficacy, along with a favorable safety profile, highlighted in this publication are encouraging. I am excited about the potential of NX-13 and immunometabolism in breaking the inflammatory cycle in UC, which remains a significant unmet need in effectively treating patients.”

Betsy Goodfellow

Related Content

Amphista doses first patient in AML trial of protein degrader

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Tridem begins phase Ib trial of Parkinson’s disease vaccine

Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

How will biomarker-led diagnostics reshape respiratory medicine?

By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …

The Gateway to Local Adoption Series

Latest content